SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia293 Stable ...

Proteomics-informed, genome-edited CHO design increased productivity up to three-fold and titers two-fold, strengthening CLD for novel biologics and biosimilars. Extended culture robustness was ...

Insourcing cell-line development has helped a fast-growing antibody manufacturer to deliver process improvements and strengthen communication with their contract manufacturer, according to Genmab, ...

LAUSANNE, Switzerland--(BUSINESS WIRE)--NewBiologix SA emerged from stealth today as a technology innovation company developing a proprietary and breakthrough platform for the advanced engineering of ...

TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. The platform has achieved ...

SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of Good Manufacturing Practices (GMP), cutting-edge, induced pluripotent stem cell (iPSC) technologies, today announced the immediate ...

Discover how to streamline your cell line development process for recombinant protein and monoclonal antibody production with this in-depth eBook. Whether you're working with CHO, HEK293, or hybridoma ...

If you’ve ever had to pause a promising experiment while waiting on titer results, you’re not alone. In many labs, samples come off the bioreactor only to sit in line for ELISA or HPLC - and decisions ...

Cell line development continues to face technical and operational hurdles in transfection, clone selection, and media optimization. Manual screening, extended culture timelines, and fragmented data ...

Aragen Biologics launched CHOMax™, a new cell line development and early manufacturing platform that the company says supports an integrated path from DNA to IND-enabling clinical supply for suitable ...